Alpine Immune Sciences, Inc. (ALPN)
| Market Cap | 242.98M |
| Revenue (ttm) | 17.95M |
| Net Income (ttm) | -34.15M |
| Shares Out | 23.91M |
| EPS (ttm) | -1.46 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 46,950 |
| Open | 10.97 |
| Previous Close | 10.66 |
| Day's Range | 10.58 - 10.98 |
| 52-Week Range | 7.21 - 16.37 |
| Beta | 1.73 |
| Analysts | Strong Buy |
| Price Target | 20.00 (+88.5%) |
| Est. Earnings Date | Nov 11, 2021 |
About ALPN
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B...
Financial Performance
In 2020, ALPN's revenue was $9.34 million, an increase of 436.49% compared to the previous year's $1.74 million. Losses were -$27.94 million, -33.24% less than in 2019.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for ALPN stock is "Strong Buy." The 12-month stock price forecast is 20.00, which is an increase of 88.50% from the latest price.
News
Alpine Immune Sciences Announces $91 Million Private Placement
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory di...
Alpine Immune Sciences Announces Participation in September Investor Conferences
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences Announces Participation in September Investor Conferences
Alpine Immune Sciences, Inc. (ALPN) Reports Q2 Loss, Tops Revenue Estimates
Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of -58.62% and 9.15%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Alpine Immune Sciences: Q2 Earnings Insights
Shares of Alpine Immune Sciences (NASDAQ:ALPN) moved higher in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 13.21% year over year to ($0.46), whi...
Alpine Immune Sciences Provides Corporate Update and Reports Second Quarter 2021 Financial Results
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences Provides Corporate Update and Reports Second Quarter 2021 Financial Results
Alpine Immune Sciences to Report Second Quarter 2021 Financial Results and to Present at Upcoming Investor Conferences
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences to Report Second Quarter 2021 Financial Results and to Present at Upcoming Investor Conferences
Will Alpine Immune Sciences, Inc. (ALPN) Report Negative Q2 Earnings? What You Should Know
Alpine Immune Sciences, Inc. (ALPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alpine Immune Sciences Initiates Trial Collaboration With Merck
Alpine Immune Sciences Inc (NASDAQ: ALPN) has entered into a clinical trial collaboration and supply agreement with Merck & Co Inc (NYSE: MRK). This collaboration will evaluate the safety and efficacy ...
Alpine Immune Sciences to Collaborate with Merck on Immuno-Oncology Study to Evaluate ALPN-202 in Combination with KE...
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences to Collaborate with Merck on Immuno-Oncology Study to Evaluate ALPN-202 in Combination with KEYTRUDA® (pembrolizumab)
Alpine Immune Sciences Announces First Patient Dosed in Synergy, ALPN-101 Phase 2 Lupus Clinical Trial and $45 millio...
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences Announces First Patient Dosed in Synergy, ALPN-101 Phase 2 Lupus Clinical Trial and $45 million in Development Milestones
Forget Biogen: These 2 Under-the-Radar Biotechs Are Also Celebrating Breakthroughs
Biogen isn't the only company whose shares should benefit from a breakthrough drug.
Alpine Immune Sciences Set to Join Russell 3000® Index
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences set to join Russell 3000® Index
Alpine Immune Sciences Announces ALPN-202 Clinical Data Presented at the 2021 ASCO Virtual Annual Meeting
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences Announces ALPN-202 Clinical Data Presented at the 2021 ASCO Virtual Annual Meeting
Alpine Immune Sciences' Autoimmune Disease Candidate ALPN-303 Shows Promise in Preclinical Studies
Alpine Immune Sciences Inc (NASDAQ: ALPN) has presented the preclinical data from its ALPN-303 program at the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology...
Alpine Immune Sciences Presents ALPN-303 Data During the 2021 EULAR Virtual Meeting
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences Presents ALPN-303 Data During the 2021 EULAR Virtual Meeting
Alpine Immune Sciences Appoints Zelanna Goldberg, M.D., M.A.S. as Chief Medical Officer
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences Appoints Zelanna Goldberg, M.D., M.A.S. as Chief Medical Officer
3 Biotech Stocks That Jumped Higher Last Week
Find out what pushed them up to see if the good times can keep rolling.
Alpine Immune Sciences, Inc. (ALPN) Moves 9.5% Higher: Will This Strength Last?
Alpine Immune Sciences, Inc. (ALPN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could ...
Alpine Immune Sciences To Host Investor Event at 2021 ASCO Virtual Annual Meeting
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences To Host Investor Event at 2021 ASCO Virtual Annual Meeting
Alpine Immune Sciences Announces Oral Presentation at the 2021 EULAR Virtual Meeting
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences Announces Oral Presentation at the 2021 EULAR Virtual Meeting
Alpine Immune Sciences, Inc. (ALPN) Reports Q1 Loss, Lags Revenue Estimates
Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of -40.63% and -45.14%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the ...
Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2021 Financial Results
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2021 Financial Results
Earnings Preview: Alpine Immune Sciences, Inc. (ALPN) Q1 Earnings Expected to Decline
Alpine Immune Sciences, Inc. (ALPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alpine Immune Sciences to Present ALPN-202 Clinical Data at the 2021 ASCO Virtual Annual Meeting
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences to Present ALPN-202 Clinical Data at the 2021 ASCO Virtual Annual Meeting
Is the Options Market Predicting a Spike in Alpine (ALPN) Stock?
Investors need to pay close attention to Alpine (ALPN) stock based on the movements in the options market lately.